Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 364

1.

Endotyping of progressive fibrotic interstitial lung diseases: It is the final destination that matters and not the journey.

Tzouvelekis A, Bouros D.

EBioMedicine. 2020 Jan 2;51:102591. doi: 10.1016/j.ebiom.2019.11.052. [Epub ahead of print] No abstract available.

2.

Low penetrance of antibiotics in the epithelial lining fluid. The role of inhaled antibiotics in patients with bronchiectasis.

Karampitsakos T, Papaioannou O, Kaponi M, Kozanidou A, Hillas G, Stavropoulou E, Bouros D, Dimakou K.

Pulm Pharmacol Ther. 2020 Feb;60:101885. doi: 10.1016/j.pupt.2019.101885. Epub 2019 Dec 28. Review.

PMID:
31891761
3.

Prospective evAluatIon foR inhalation devices in Greek patients with COPD and asthma: The PAIR study.

Karampitsakos T, Hillas G, Zervas E, Bakakos P, Stratakos G, Dimakou K, Manali E, Bouros D, Papiris S, Tzouvelekis A; PAIR study investigators.

Pulm Pharmacol Ther. 2020 Feb;60:101882. doi: 10.1016/j.pupt.2019.101882. Epub 2019 Dec 24.

PMID:
31881275
4.

Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study in Greece.

Tzouvelekis A, Karampitsakos T, Gomatou G, Bouros E, Tzilas V, Manali E, Tomos I, Trachalaki A, Kolilekas L, Korbila I, Tomos P, Chrysikos S, Gaga M, Daniil Z, Bardaka F, Papanikolaou IC, Euthymiou C, Papakosta D, Steiropoulos P, Ntolios P, Tringidou R, Papiris S, Antoniou K, Bouros D.

Pulm Pharmacol Ther. 2020 Feb;60:101880. doi: 10.1016/j.pupt.2019.101880. Epub 2019 Dec 23.

PMID:
31874284
5.

The role of increased red cell distribution width as a negative prognostic marker in patients with COPD.

Karampitsakos T, Dimakou K, Papaioannou O, Chrysikos S, Kaponi M, Bouros D, Tzouvelekis A, Hillas G.

Pulm Pharmacol Ther. 2020 Feb;60:101877. doi: 10.1016/j.pupt.2019.101877. Epub 2019 Dec 13.

PMID:
31843703
6.

Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease.

Wuyts WA, Wijsenbeek M, Bondue B, Bouros D, Bresser P, Robalo Cordeiro C, Hilberg O, Magnusson J, Manali ED, Morais A, Papiris S, Shaker S, Veltkamp M, Bendstrup E.

Respiration. 2020;99(1):73-82. doi: 10.1159/000504763. Epub 2019 Dec 12. Review.

7.

Interstitial Lung Abnormalities: A Word of Caution.

Tzilas V, Bouros D.

Chest. 2019 Dec;156(6):1037-1038. doi: 10.1016/j.chest.2019.08.2170. No abstract available.

PMID:
31812187
8.

A role of antifibrotics in the treatment of Scleroderma-ILD?

Antoniou KM, Trachalaki A, Tzouvelekis A, Poletti V, Vasarmidi E, Sfikakis P, Bouros D.

Pulmonology. 2020 Jan - Feb;26(1):1-2. doi: 10.1016/j.pulmoe.2019.08.004. Epub 2019 Oct 23. No abstract available.

9.

Role of dual-specificity protein phosphatase DUSP10/MKP-5 in pulmonary fibrosis.

Xylourgidis N, Min K, Ahangari F, Yu G, Herazo-Maya JD, Karampitsakos T, Aidinis V, Binzenhöfer L, Bouros D, Bennett AM, Kaminski N, Tzouvelekis A.

Am J Physiol Lung Cell Mol Physiol. 2019 Nov 1;317(5):L678-L689. doi: 10.1152/ajplung.00264.2018. Epub 2019 Sep 4.

PMID:
31483681
10.

Estrogen Signaling and MicroRNAs in Lung Fibrosis. Sex, Hormones, and Rock Scars.

Tzouvelekis A, Bouros D.

Am J Respir Crit Care Med. 2019 Nov 15;200(10):1199-1200. doi: 10.1164/rccm.201908-1535ED. No abstract available.

11.

Myelodysplastic syndromes and idiopathic pulmonary fibrosis: a dangerous liaison.

Papiris SA, Tsirigotis P, Kannengiesser C, Kolilekas L, Gkirkas K, Papaioannou AI, Revy P, Giouleka P, Papadaki G, Kagouridis K, Pappa V, Borie R, Boileau C, Bouros D, Crestani B, Manali ED.

Respir Res. 2019 Aug 13;20(1):182. doi: 10.1186/s12931-019-1151-6.

12.

A 63-Year-Old Woman With Pulmonary Micronodules and Chronic Cough.

Tzilas V, Kyriazis P, Tzouvelekis A, Vachlas K, Frangia K, Bouros D.

Chest. 2019 Aug;156(2):e47-e50. doi: 10.1016/j.chest.2019.03.034.

PMID:
31395268
13.

Telomeropathy in Chronic Hypersensitivity Pneumonitis.

Bouros D, Tzouvelekis A.

Am J Respir Crit Care Med. 2019 Nov 1;200(9):1086-1087. doi: 10.1164/rccm.201907-1483ED. No abstract available.

14.

Autoimmune Biomarkers, Antibodies, and Immunologic Evaluation of the Patient with Fibrotic Lung Disease.

Tzouvelekis A, Karampitsakos T, Bouros E, Tzilas V, Liossis SN, Bouros D.

Clin Chest Med. 2019 Sep;40(3):679-691. doi: 10.1016/j.ccm.2019.06.002. Review.

PMID:
31376900
15.

Diagnostic value of BAL lymphocytosis in patients with indeterminate for usual interstitial pneumonia imaging pattern.

Tzilas V, Tzouvelekis A, Bouros E, Karampitsakos T, Ntasiou M, Katsaras M, Costabel U, Wells A, Bouros D.

Eur Respir J. 2019 Nov 14;54(5). pii: 1901144. doi: 10.1183/13993003.01144-2019. Print 2019 Nov. No abstract available.

PMID:
31320457
16.

Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer.

Tzouvelekis A, Gomatou G, Bouros E, Trigidou R, Tzilas V, Bouros D.

Chest. 2019 Aug;156(2):383-391. doi: 10.1016/j.chest.2019.04.114. Epub 2019 May 22. Review.

PMID:
31125557
17.

Human pentraxin 2 protein treatment for IPF.

Tzouvelekis A, Tzilas V, Antoniou KM, Bouros D.

Lancet Respir Med. 2019 Aug;7(8):640-641. doi: 10.1016/S2213-2600(19)30173-0. Epub 2019 May 20. No abstract available.

PMID:
31122900
18.

Safety and Efficacy of Early and Long-Term Use of Pirfenidone in Idiopathic Pulmonary Fibrosis.

Tzilas V, Tzouvelekis A, Bouros D.

Respiration. 2019;98(1):16-18. doi: 10.1159/000497391. Epub 2019 Apr 4. No abstract available.

PMID:
30947205
19.

Interstitial lung abnormalities: ignotum per ignotius.

Antoniou KM, Tzilas V, Vasarmidi E, Symvoulakis EK, Tzouvelekis A, Bouros D.

Lancet Respir Med. 2019 May;7(5):376-378. doi: 10.1016/S2213-2600(19)30052-9. Epub 2019 Mar 29. No abstract available.

PMID:
30935882
20.

Biologic Treatments in Interstitial Lung Diseases.

Karampitsakos T, Vraka A, Bouros D, Liossis SN, Tzouvelekis A.

Front Med (Lausanne). 2019 Mar 13;6:41. doi: 10.3389/fmed.2019.00041. eCollection 2019. Review.

21.

Combined pulmonary fibrosis and emphysema characteristics in a Greek cohort.

Malli F, Papakosta D, Antoniou K, Dimadi M, Polychronopoulos V, Malagari K, Oikonomou A, Bouros DE, Daniil Z.

ERJ Open Res. 2019 Mar 18;5(1). pii: 00014-2018. doi: 10.1183/23120541.00014-2018. eCollection 2019 Feb.

22.

Idiopathic interstitial pneumonia or idiopathic interstitial pneumonitis: what's in a name?

Kolilekas L, Costabel U, Tzouvelekis A, Tzilas V, Bouros D.

Eur Respir J. 2019 Feb 14;53(2). pii: 1800994. doi: 10.1183/13993003.00994-2018. Print 2019 Feb. No abstract available.

PMID:
30765482
23.

Vitamin D prevents experimental lung fibrosis and predicts survival in patients with idiopathic pulmonary fibrosis.

Tzilas V, Bouros E, Barbayianni I, Karampitsakos T, Kourtidou S, Ntassiou M, Ninou I, Aidinis V, Bouros D, Tzouvelekis A.

Pulm Pharmacol Ther. 2019 Apr;55:17-24. doi: 10.1016/j.pupt.2019.01.003. Epub 2019 Jan 16.

PMID:
30659895
24.

Existing and emerging treatments for idiopathic pulmonary fibrosis.

Kolilekas L, Papiris S, Bouros D.

Expert Rev Respir Med. 2019 Mar;13(3):229-239. doi: 10.1080/17476348.2019.1568244. Epub 2019 Jan 21.

PMID:
30632421
25.

Crazy paving pattern as a rare radiological manifestation of peripheral T-cell lymphoma (PTCL) with lung involvement: A case report.

Gomatou G, Tzilas V, Kourti G, Lagou S, Bouros D, Syrigos K.

Respir Med Case Rep. 2018 Sep 26;25:253-256. doi: 10.1016/j.rmcr.2018.09.015. eCollection 2018.

26.

Diagnostic guidelines for IPF: when art meets science.

Bouros D, Tzilas V, Tzouvelekis A.

Lancet Respir Med. 2018 Nov;6(11):812-814. doi: 10.1016/S2213-2600(18)30430-2. No abstract available.

PMID:
30484427
27.

Lung function changes after chemoradiation therapy in patients with lung cancer treated by three usual platinum combinations.

Mihailidis V, Anevlavis S, Karpathiou G, Kouliatsis G, Tzouvelekis A, Zarogoulidis P, Ntolios P, Steiropoulos P, Bouros D, Froudarakis ME.

J Thorac Dis. 2018 Sep;10(9):5435-5442. doi: 10.21037/jtd.2018.08.139.

28.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.

PMID:
30168753
29.

Metformin in Idiopathic Pulmonary Fibrosis "Seeking the Holy-Grail through Drug-Repositioning".

Tzouvelekis A, Tzilas V, Dassiou M, Bouros D.

Respiration. 2018;96(4):305-307. doi: 10.1159/000490917. Epub 2018 Jul 13. No abstract available.

30.

Prognosis of Interstitial Lung Disease Associated with Anti-Aminoacyl-tRNA Synthetase Antibodies: Look in the Middle.

Tzilas V, Tzouvelekis A, Bouros E, Bouros D.

Respiration. 2018;96(3):207-209. doi: 10.1159/000489936. Epub 2018 Jun 19. No abstract available.

31.

Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis.

Tzouvelekis A, Toonkel R, Karampitsakos T, Medapalli K, Ninou I, Aidinis V, Bouros D, Glassberg MK.

Front Med (Lausanne). 2018 May 15;5:142. doi: 10.3389/fmed.2018.00142. eCollection 2018. Review.

32.

The Autotaxin-Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis.

Magkrioti C, Oikonomou N, Kaffe E, Mouratis MA, Xylourgidis N, Barbayianni I, Megadoukas P, Harokopos V, Valavanis C, Chun J, Kosma A, Stathopoulos GT, Bouros E, Bouros D, Syrigos K, Aidinis V.

Cancer Res. 2018 Jul 1;78(13):3634-3644. doi: 10.1158/0008-5472.CAN-17-3797. Epub 2018 May 3.

33.

Nintedanib in Severe Idiopathic Pulmonary Fibrosis: Effectiveness through Compassion.

Tzouvelekis A, Bouros D.

Respiration. 2018;95(6):401-402. doi: 10.1159/000488647. Epub 2018 Apr 25. No abstract available.

34.

Pulmonary hypertension in patients with interstitial lung disease.

Karampitsakos T, Tzouvelekis A, Chrysikos S, Bouros D, Tsangaris I, Fares WH.

Pulm Pharmacol Ther. 2018 Jun;50:38-46. doi: 10.1016/j.pupt.2018.03.002. Epub 2018 Mar 29. Review.

PMID:
29605286
35.

Design, Rationale, Methodology, and Aims of a Greek Prospective Idiopathic Pulmonary Fibrosis Registry: Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF).

Bouros D, Daniil Z, Papakosta D, Antoniou KM, Markopoulou K, Kolilekas L, Konstantopoulos G, Papiris S; INDULGE IPF Study Group.

Respiration. 2018 Mar 7;96(1):41-47. doi: 10.1159/000487244. [Epub ahead of print]

36.

A Rare Case of Primary Intrapulmonary Neurilemmoma Diagnosed in a 43-Year-Old Asymptomatic Man with a Well-defined Intrapulmonary Mass.

Chrysikos S, Kaponi M, Triantafillidou C, Karampitsakos T, Tzouvelekis A, Anyfanti M, Marossis K, Konstantinou M, Tringidou R, Bouros D, Dimakou K.

Front Oncol. 2018 Jan 30;8:11. doi: 10.3389/fonc.2018.00011. eCollection 2018.

37.

Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the adipose-derived stromal cells-stromal vascular fraction in idiopathic pulmonary fibrosis.

Ntolios P, Manoloudi E, Tzouvelekis A, Bouros E, Steiropoulos P, Anevlavis S, Bouros D, Froudarakis ME.

Clin Respir J. 2018 Jun;12(6):2084-2089. doi: 10.1111/crj.12777. Epub 2018 Mar 12.

PMID:
29412521
38.

Metabolic Disorders in Chronic Lung Diseases.

Papaioannou O, Karampitsakos T, Barbayianni I, Chrysikos S, Xylourgidis N, Tzilas V, Bouros D, Aidinis V, Tzouvelekis A.

Front Med (Lausanne). 2018 Jan 18;4:246. doi: 10.3389/fmed.2017.00246. eCollection 2017. Review.

39.

Corrigendum: Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N, Bouros D.

Front Med (Lausanne). 2018 Jan 24;4:257. doi: 10.3389/fmed.2017.00257. eCollection 2017.

40.

Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.

Tzouvelekis A, Karampitsakos T, Kontou M, Granitsas A, Malliou I, Anagnostopoulos A, Ntolios P, Tzilas V, Bouros E, Steiropoulos P, Chrysikos S, Dimakou K, Koulouris N, Bouros D.

Pulm Pharmacol Ther. 2018 Apr;49:61-66. doi: 10.1016/j.pupt.2018.01.006. Epub 2018 Jan 31.

PMID:
29366978
41.

Patients with IPF and lung cancer: diagnosis and management.

Tzouvelekis A, Spagnolo P, Bonella F, Vancheri C, Tzilas V, Crestani B, Kreuter M, Bouros D.

Lancet Respir Med. 2018 Feb;6(2):86-88. doi: 10.1016/S2213-2600(17)30478-2. Epub 2017 Dec 11. Review. No abstract available.

PMID:
29241977
42.

Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N, Bouros D.

Front Med (Lausanne). 2017 Nov 29;4:213. doi: 10.3389/fmed.2017.00213. eCollection 2017. Erratum in: Front Med (Lausanne). 2018 Jan 24;4:257.

43.

Taking a giant step in the diagnosis of idiopathic pulmonary fibrosis.

Tzilas V, Valeyre D, Tzouvelekis A, Bouros D.

Lancet Respir Med. 2018 Feb;6(2):82-84. doi: 10.1016/S2213-2600(17)30443-5. Epub 2017 Nov 15. No abstract available.

PMID:
29154105
44.

Metsovo Lung: A Story of Episteme, Techne, and Phronesis.

Tzilas V, Tzouvelekis A, Bouros D.

Respiration. 2017;94(6):491-492. doi: 10.1159/000481291. Epub 2017 Oct 13. No abstract available.

45.

Diagnosis of Idiopathic Pulmonary Fibrosis "Pragmatic Challenges in Clinical Practice".

Tzilas V, Tzouvelekis A, Chrysikos S, Papiris S, Bouros D.

Front Med (Lausanne). 2017 Sep 20;4:151. doi: 10.3389/fmed.2017.00151. eCollection 2017. Review.

46.

The effect of bronchodilation and spirometry on fractional exhaled nitric oxide (FeNO50), bronchial NO flux (JawNO) and alveolar NO concentration (CANO) in children and young adults.

Karampitsakos T, Protopapas A, Gianoloudi M, Papadopoulos VP, Bouros D, Chatzimichael A, Paraskakis E.

J Asthma. 2018 Aug;55(8):882-889. doi: 10.1080/02770903.2017.1373807. Epub 2017 Oct 11.

PMID:
28949783
47.

Pirfenidone in Idiopathic Pulmonary Fibrosis "RECAP-itulating Safety into the Real World".

Tzouvelekis A, Bouros E, Tzilas V, Bouros D.

Respiration. 2017;94(5):405-407. doi: 10.1159/000480299. Epub 2017 Sep 5. No abstract available.

48.

Lung fibrosis-associated soluble mediators and bronchoalveolar lavage from idiopathic pulmonary fibrosis patients promote the expression of fibrogenic factors in subepithelial lung myofibroblasts.

Bouros E, Filidou E, Arvanitidis K, Mikroulis D, Steiropoulos P, Bamias G, Bouros D, Kolios G.

Pulm Pharmacol Ther. 2017 Oct;46:78-87. doi: 10.1016/j.pupt.2017.08.012. Epub 2017 Sep 1.

PMID:
28865842
49.

Chronic Kidney Disease and Idiopathic Pulmonary Fibrosis: Thinking Outside the Box in Disease Management and Prognostication.

Tzouvelekis A, Bouros E, Bouros D.

Respiration. 2017;94(4):334-335. doi: 10.1159/000480093. Epub 2017 Aug 26. No abstract available.

50.

Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis: A real-world observational study.

Tzouvelekis A, Ntolios P, Karampitsakos T, Tzilas V, Anevlavis S, Bouros E, Steiropoulos P, Koulouris N, Stratakos G, Froudarakis M, Bouros D.

Pulm Pharmacol Ther. 2017 Oct;46:48-53. doi: 10.1016/j.pupt.2017.08.011. Epub 2017 Aug 24.

PMID:
28843616

Supplemental Content

Loading ...
Support Center